These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 23013419)

  • 41. Pathogenetic mechanisms of vitiligo in a patient with Sézary syndrome.
    Knol AC; Quéreux G; Marques-Briand S; Pandolfino MC; Khammari A; Guilloux Y; Dreno B
    Br J Dermatol; 2005 Dec; 153(6):1207-12. PubMed ID: 16307660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune effects of interferon gamma in persistent staphylococcal sepsis.
    Nalos M; Santner-Nanan B; Parnell G; Tang B; McLean AS; Nanan R
    Am J Respir Crit Care Med; 2012 Jan; 185(1):110-2. PubMed ID: 22210794
    [No Abstract]   [Full Text] [Related]  

  • 43. Malignant and nonmalignant T cell lines from human T cell lymphotropic virus type I-negative patients with Sézary syndrome.
    Abrams JT; Lessin SR; Ghosh SK; Nowell PC; Ju W; Vonderheid EC; Rook AH; DeFreitas E
    J Immunol; 1991 Mar; 146(5):1455-62. PubMed ID: 1847162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interleukin-7 is a growth factor for Sézary lymphoma cells.
    Dalloul A; Laroche L; Bagot M; Mossalayi MD; Fourcade C; Thacker DJ; Hogge DE; Merle-Béral H; Debré P; Schmitt C
    J Clin Invest; 1992 Sep; 90(3):1054-60. PubMed ID: 1381718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IgE reactivity and survival probabilities in Sézary syndrome.
    Scala E; Abeni D; Russo G; Narducci MG
    J Am Acad Dermatol; 2015 Jun; 72(6):e177. PubMed ID: 25981030
    [No Abstract]   [Full Text] [Related]  

  • 46. Reply to: "IgE reactivity and survival probabilities in Sézary syndrome".
    Väkevä L; Mäkinen-Kiljunen S; Ranki A
    J Am Acad Dermatol; 2015 Jun; 72(6):e179. PubMed ID: 25981031
    [No Abstract]   [Full Text] [Related]  

  • 47. Increased Expression of PLS3 Correlates with Better Outcome in Sézary Syndrome.
    Boonk SE; Zoutman WH; Putter H; Ram-Wolff C; Felcht M; Klemke CD; Ranki A; Quaglino P; Whittaker S; Bagot M; Willemze R; Vermeer MH
    J Invest Dermatol; 2017 Mar; 137(3):754-757. PubMed ID: 27984038
    [No Abstract]   [Full Text] [Related]  

  • 48. Vacuolation of early erythroblasts with ring sideroblasts: a clue to the diagnosis of linezolid toxicity.
    Liapis K; Vrachiolias G; Spanoudakis E; Kotsianidis I
    Br J Haematol; 2020 Sep; 190(6):809. PubMed ID: 32510577
    [No Abstract]   [Full Text] [Related]  

  • 49. Production of chemotactic factor for Sézary cell by A431, K-TL-1.
    Yamada H; Orita T; Harada M; Tezuka T
    Dermatologica; 1989; 179 Suppl 1():120. PubMed ID: 2476338
    [No Abstract]   [Full Text] [Related]  

  • 50. Factor V: an active player in inflammation.
    Sun H
    Blood; 2015 Nov; 126(21):2352-3. PubMed ID: 26585805
    [No Abstract]   [Full Text] [Related]  

  • 51. Presepsin - the new kid on the sepsis block.
    Faix JD
    Clin Biochem; 2014 May; 47(7-8):503-4. PubMed ID: 24769276
    [No Abstract]   [Full Text] [Related]  

  • 52. Diabetes and sepsis: preclinical findings and clinical relevance.
    Schuetz P; Castro P; Shapiro NI
    Diabetes Care; 2011 Mar; 34(3):771-8. PubMed ID: 21357364
    [No Abstract]   [Full Text] [Related]  

  • 53. Interleukin-34: A New Player in the Sepsis Arena.
    Jacobs MC; Wiersinga WJ
    Crit Care Med; 2018 Jun; 46(6):1032-1033. PubMed ID: 29762412
    [No Abstract]   [Full Text] [Related]  

  • 54. Interleukin-26 is a promising biomarker of sepsis but is it always reliable?
    Honore PM; Mugisha A; Barreto Gutierrez L; Redant S; Kaefer K; Gallerani A; De Bels D
    Crit Care; 2019 Dec; 23(1):397. PubMed ID: 31810467
    [No Abstract]   [Full Text] [Related]  

  • 55. Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas.
    Kołkowski K; Trzeciak M; Sokołowska-Wojdyło M
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protein and mRNA Expression Levels of Interleukin-17A, -17F and -22 in Blood and Skin Samples of Patients with Mycosis Fungoides.
    Papathemeli D; Patsatsi A; Papanastassiou D; Koletsa T; Papathemelis T; Avgeros C; Pikou O; Lazaridou E; Georgiou E
    Acta Derm Venereol; 2020 Nov; 100(18):adv00326. PubMed ID: 33170303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.
    Fujii K
    Front Oncol; 2018; 8():198. PubMed ID: 29915722
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of interleukin-22 in inflammatory bowel disease.
    Li LJ; Gong C; Zhao MH; Feng BS
    World J Gastroenterol; 2014 Dec; 20(48):18177-88. PubMed ID: 25561785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD8+ Sézary syndrome with interleukin-22 production modulated by bacterial sepsis.
    Shimauchi T; Sasada K; Kito Y; Mori T; Hata M; Fujiyama T; Ito T; Hirakawa S; Tokura Y
    Br J Dermatol; 2013 Apr; 168(4):881-3. PubMed ID: 23013419
    [No Abstract]   [Full Text] [Related]  

  • 60. Cutaneous colonization with staphylococci influences the disease activity of Sézary syndrome: a potential role for bacterial superantigens.
    Tokura Y; Yagi H; Ohshima A; Kurokawa S; Wakita H; Yokote R; Shirahama S; Furukawa F; Takigawa M
    Br J Dermatol; 1995 Jul; 133(1):6-12. PubMed ID: 7669641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.